Amelanotic malignant melanoma: clinicopathologic features

  • Strazzulla LC & al.
  • J Am Acad Dermatol
  • 14/01/2019

  • Brian Richardson, PhD
  • Univadis Clinical Summaries
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • A retrospective study identifies clinicopathologic factors associated with amelanotic metastatic melanoma (AMM) compared with pigmented MM (PMM).

Why this matters

  • AMM is difficult to diagnose, and risk factors for AMM are poorly understood.

Key results

  • Patients with AMM were older (OR, 1.03; P<.001 more likely to have history of nonmelanoma skin cancer and red hair less a family mm>50 nevi (OR, 0.38; P<.001 or history of dysplastic nevi compared with patients pmm.>
  • Patients with AMM were more likely to have head/neck disease site (OR, 1.87; P=.002), ulceration (OR, 1.69; P<.001 and nodular subtype had greater breslow depth mitotic rate were less likely to have precursor nevi or tumor regression compared with patients>
  • AMM was associated with higher misdiagnosis rates (25% vs 12% clinically [P<.001 vs pathologically and reduced survival rates compared with pmm.>

Study design

  • 933 patients with melanoma, 342 with AMM, and 591 with PMM were analyzed.
  • Funding: NCI/NIH.

Limitations

  • Retrospective, single-center study.